Your browser doesn't support javascript.
loading
Circulating tumor cells in breast cancer: methodology and clinical repercussions
Gasent Blesa, J. M; Alberola Candel, V; Esteban González, E; Vidal Martínez, J; Gisbert Criado, R; Provencio Pulla, M; Laforga Canales, J; Pachmann, K.
Affiliation
  • Gasent Blesa, J. M; Hospital General Universitari Marina Alta. Dènia. Spain
  • Alberola Candel, V; Arnau Hospital of Vilanova. Valencia. Spain
  • Esteban González, E; Central Hospital of Asturias. Asturias. Spain
  • Vidal Martínez, J; Arnau Hospital of Vilanova. Valencia. Spain
  • Gisbert Criado, R; Arnau Hospital of Vilanova. Valencia. Spain
  • Provencio Pulla, M; Hospital Puerta de Hierro. Madrid. Spain
  • Laforga Canales, J; Hospital General Universitari Marina Alta. Dènia. Spain
  • Pachmann, K; Universität Jena. Jena. Germany
Clin. transl. oncol. (Print) ; 10(7): 399-406, jul. 2008. tab
Article in English | IBECS | ID: ibc-123470
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Breast cancer is the most common type of cancer among women, and clinicians have long recognized its heterogeneity. Its detection and treatment in early stages allow for reduction of mortality. Despite the advances and new strategies for combining surgical, radiotherapy, and chemotherapy options, however, the percentage of patients developing metastases and advanced stages remains high. Even though serum tumor markers have been used for the early diagnosis of metastases, their systematic determination has not had an effect on survival. Methods that are more reliable are needed to detect metastases earlier than with the common clinical methods and thus start treatment before overt relapse. Early indicators of response or resistance to treatment are also an issue in clinical practice. Imaging techniques are time consuming, and it is difficult to detect changes that indicate response limited to therapy, and approaches to defining changes in tumor mass are time and resource consuming. In contrast, detection of circulating tumor cells (CTC) could be a useful tool in early detection of relapse and response to systemic chemotherapy. Extremely sensitive techniques are available that are easily applied to peripheral blood samples, which might provide enormous research possibilities in this area (AU)
RESUMEN
No disponible
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Breast Cancer Database: IBECS Main subject: Breast Neoplasms / Hematologic Tests / Neoplastic Cells, Circulating Type of study: Screening study Limits: Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2008 Document type: Article Institution/Affiliation country: Arnau Hospital of Vilanova/Spain / Central Hospital of Asturias/Spain / Hospital General Universitari Marina Alta/Spain / Hospital Puerta de Hierro/Spain / Universität Jena/Germany
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Breast Cancer Database: IBECS Main subject: Breast Neoplasms / Hematologic Tests / Neoplastic Cells, Circulating Type of study: Screening study Limits: Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2008 Document type: Article Institution/Affiliation country: Arnau Hospital of Vilanova/Spain / Central Hospital of Asturias/Spain / Hospital General Universitari Marina Alta/Spain / Hospital Puerta de Hierro/Spain / Universität Jena/Germany
...